The 2020 Benzinga Cannabis Capital Conference In Detroit Will Be Moving Online

Due to continuing concerns surrounding COVID-19, Benzinga will be bringing its Cannabis Capital Conference online. Originally scheduled to take place in Detroit, this conference will focus on carefully vetted companies in the emerging Michigan market.

The event, set to take place on Tuesday, August 18, 2020, will serve as a meeting place for cannabis investors, entrepreneurs, and leaders in the cannabis industry.

Attendees can look forward to round table discussions and panels with top cannabis entrepreneurs, keynote quick fires, and investor presentations. The main aim of the Cannabis Capital Conference is to foster connections within the cannabis industry and create new and exciting opportunities.

The previous Virtual Cannabis Capital Conference featured presentations from companies such as Columbia Care Inc (OTC: CCHWF), KushCo Holdings Inc (OTC: KSHB), Trulieve Cannabis (OTC: TCNNF), Valens Groworks Corp (OTC: VLNCF), MariMed Inc (OTC: MRMD), among many others.

“We found the event, the turnout, and the content to be of amazing high quality and well worth our time,” said Rod Weiss, Vice President of Operations at BlueSky Organics. “Both myself and our CEO Mary Horvatincic found [the] June 1st event and [Benzinga’s] personal moderation of videos to be highly professional.”

For more information or to register for the Virtual Cannabis Capital Conference, visit: https://www.benzinga.com/events/cannabis/detroit/

About Benzinga

Benzinga is a leading financial media company dedicated to making information easier to consume. Benzinga’s news desk is constantly breaking stories and moving billions of dollars of market capitalization through its real-time news tool, Benzinga Pro. Benzinga’s original content is syndicated to 70 partner websites including Yahoo! Finance MSN, CNNMoney, Fox Business and MarketWatch.

Cannabis Capital Conference Contact:
www.benzingacannabisconference.com
877.440-9464 (ZING)
Sarah Winner | Speaker Relations Director
events@benzinga.com

Media Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments

CannabisNewsWire Editorial Coverage: Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has recently seen spectacular improvements in the effectiveness of cannabinoids thanks to its proprietary chemical delivery treatment. GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF), which has won widespread praise for its innovative medical work, has seen good trial results for a new treatment for seizures.  Tilray Inc. (NASDAQ: TLRY) is supporting studies into the uses of cannabinoids to treat behavioral problems and HIV. MariMed Inc. (OTCQB: MRMD) has set up a subsidiary focused on CBD, currently the highest-profile cannabinoid product. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) has established a new research lab to develop devices for CBD consumption.

  • Currently, cannabis medicines are poorly absorbed by the body.
  • Delivery challenges increase costs and reduce effectiveness.
  • Select companies are working on better delivery systems.
  • Others are working on new medicines so that cannabinoids can improve more lives.

To view an infographic of this editorial, click here.

The Cannabinoid Waste Conundrum

The popularity of cannabinoid products — those containing active ingredients from cannabis — has created a challenge for producers. While these producers are extracting larger volumes of CBD from cannabis and hemp, much of the precious ingredient goes to waste: the human body only absorbs a small fraction of these molecules because of delivery system limitations and human physiology.

This delivery challenge causes several problems. Manufacturers must comply with regulations limiting the amount of active cannabinoid ingredients, but consumers may not be able to obtain the effect or benefit they are seeking, even when needed to overcome serious medical conditions. People could end up consuming more cannabis than they would otherwise, which is both expensive and ill-advised. And in an age when the waste of human society is ravaging the environment, it means that the cannabis industry may also be doing unneeded damage to the environment.

But thanks to the fast pace of cannabis research, a solution may be on the horizon.

Improving the Delivery of Cannabinoids

Across the industry, researchers are looking for ways to more effectively deliver CBD into the human body. Thanks to their latest breakthroughs, the scientists at Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) appear to be leading the way.

A biotech company based in British Columbia, Lexaria is currently focusing on its proprietary DehydraTECH(TM) technology. This unique technology has been developed to make medicinal compounds more suitable for human consumption in a number of ways. By combining molecules such as CBD with fatty acids at a molecular level, DehydraTECH makes it easier for the CBD to cross the body’s internal barriers. Higher levels of CBD are absorbed, and they are absorbed more quickly.

Consumers need to know this: the quantity of CBD, or any other drug, in the bottle is unimportant. What matters is how much of that CBD actually reaches the bloodstream — and even more importantly — how much reaches the brain.

Most CBD sold in CBD-infused products in America today does not reach the bloodstream. CBD mixed in water and fed to animals demonstrated the incredible power of DehydraTECH. Results announced in May showed that DehydraTECH, in combination with generic nanotech techniques, delivered CBD to the brain 1,137% more efficiently than existing industry formulations. In addition, Lexaria’s patented DehydraTECH delivered CBD into the bloodstream in just two minutes and delivered as much CBD in 15 minutes as generic doses did in 60 minutes.

Not content with these sorts of results, the company has been working on improving the power of DehydraTECH through a new second-generation version called Enhanced DehydraTECH. Lexaria’s Enhanced DehydraTECH showed remarkable properties in crossing the blood-brain-barrier, delivering 1,937% more CBD into the brain than a generic industry formulation. It also delivered between 717% and 1,098% more CBD into the bloodstream than generic CBD formulations.

Lexaria’s technological advances make it possible to manufacture capsules and edible products that deliver CBD and THC more effectively than ever before.

Satisfying Customers and Regulators

This vastly superior delivery performance holds promise to radically change the CBD industry, at a time when the sector is already going through huge change and growth.

On one level, the benefits of technology such as that being developed by Lexaria are obvious. A more efficient delivery system can do one of two things: it can make the same dose of a drug or vitamin more effective, or it can allow the same consumer effect to be achieved with a smaller dose.

The latter approach may have the widest impact and certainly has potential to shift prices. Recent legal changes in Canada and the United States have led to a surge in demand for CBD, a demand that suppliers have been unable to meet. With demand for CBD outstripping supply and a production process that involves complex technical steps, the price of CBD is relatively high. But if companies can make products that are just as effective but use smaller amounts of CBD, they can reduce their production costs and provide more products with the same raw resources. This change would allow companies to meet currently unmet demand and reduce prices, thus benefitting both the customers and the industry.

There’s also a less-obvious factor, one that industry outsiders might not consider but that companies such as Lexaria are acutely aware of. With the legalization of cannabis across Canada and hemp in the United States, regulators are stepping in to control the production, sale and dosage amounts of CBD or THC products. Limits are being set on how much CBD or THC a product can contain.

Improved delivery systems such as DehydraTECH allow companies to produce more effective products within the same legal limits. Customers can experience the highest benefit from their products while everyone stays inside the law.

Beyond CBD?

But while CBD is proving a profitable testing ground for DehydraTECH, the impact of this first-of-its-kind delivery system could potentially go far beyond this, extending into the wider medical sector.

Recent research results have shown that DehydraTECH is effective in delivering both cannabinoids and nicotine into brain tissue, thus improving the speed and effectiveness of these ingredients. The delivery system also comes with a fast-on/fast-off element, in which the effect of the drug both starts and ends quickly and clearly, providing better control over the use of the products in which drugs are used. DehydraTECH is being evaluated by the largest nicotine company in America for products utilizing oral delivery, bypassing the known disease conditions associated with current pulmonary delivery.

As a result, Lexaria’s technology already has potential medical benefits because it can be used to deliver CBD- and THC-based medicines, in addition to its applications as a solution to cigarette use. But what if it could do more?

Since DehydraTECH has been shown to work with multiple molecules, people are asking if it could be used with central nervous system drugs. By delivering drugs quickly and efficiently across the blood-brain-barrier, this innovative delivery system could enhance the speed and effectiveness of a wide range of drugs and potentially usher in a new era of treatment for a wide range of debilitating diseases. Lexaria has quietly filed patent applications for innovation in treatment options related to central nervous system diseases such as Parkinson’s and Alzheimers.

Experimenting with Cannabis

Given the importance of cannabinoids in treating some of these debilitating diseases, improved delivery systems already have clear medical advantages. Among the companies applying cannabinoids to life-changing medicines is GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF). With more than 20 years of research in the cannabis sector, GW is a global leader in developing cannabinoid medicines and was named one of Time Magazine’s 50 genius companies for this work. The company recently announced successful clinical trials of EPIDIOLEX, in which this CBD drug was used to reduce the frequency of seizures associated with tubular sclerosis complex.

Tilray Inc. (NASDAQ: TLRY), a world-leading cannabis company based in Canada, has been working to address the shortage of cannabis and CBD, investing $32.6 million in an expansion of its cultivation and manufacturing facilities. But the company isn’t just working on meeting current needs. Tilray is providing support to two clinical studies that could lead cannabinoids to transform more lives for the better. Through studies like these, the use of cannabinoids is spreading beyond its traditional territory of pain and nausea management.

MariMed Inc. (OTCQB: MRMD), a multistate cannabis company, has been improving the efficiency of its operations through vertical integration and the addition of new product lines, allowing it to more effectively deliver cannabis products to a wide range of customers. At the start of this year, the company established a subsidiary focused on CBD in response to rising sales and the changed legal status of hemp manufacturing in the US.

Lexaria’s work on DehyrdaTECH isn’t the only area where the interests of cannabis and tobacco are merging. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), a global cannabinoid company, has had its fortunes and its profile improved by an investment of C$2.4 billion from tobacco giant Altria. The company’s growth has also allowed it to establish a new global research and design center, Cronos Device Labs, in Israel. There, the company will work on devices specifically designed for the consumption of CBD.

As the technology around cannabis improves, so will the efficiency and effectiveness of cannabinoid products, lowering prices and improving outcomes for patients around the world.

For more information on Lexaria Bioscience Corp., visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles

CannabisNewsWire Editorial Coverage: Fueled by an explosion of CBD-infused edibles, billion-dollar projections for the CBD market may even be conservative.

This seems possible when one considers the truly innovative work being done in the sector by the likes of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile), which has developed a patented delivery technology with disruptive potential, delivering 475% more CBD to the bloodstream after 15 minutes than conventional formulations. Other sector innovators are making a similar impact, including the likes of noted cannabinoid biopharma GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF) and that of researchers and product developers Tilray Inc. (NASDAQ: TLRY), MariMed Inc. (OTCQB: MRMD) and Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB).

  • CBD is going mainstream into all kinds of consumer goods and foodstuffs.
  • Hard data on numerous health benefits appears to be core driver behind growing CBD acceptance.
  • $1 billion-plus cannabis edibles segment growing rapidly but separate from CBD market.
  • Innovative delivery tech could revolutionize the industry and consumer receptivity.

To view an infographic of this editorial, click here.

Mainstream CBD Teeing Up an Edibles Boom

The recent May 9 report from leading cannabis industry analysts BDS Analytics and Arcview Market Research forecasts that the market for nonpsychoactive cannabinoid CBD (cannabidiol) alone will hit upwards of $20 billion by 2024, running at a CAGR around 49%. With last year’s farm bill legalizing industrial hemp in the United States, CBD sales in dispensaries have been rapidly increasing. Additionally fueled by an explosion of CBD-infused edibles, it appears that conservative sector growth estimates from analysts such as New York-based investment bank Cowen & Co. may be shortsighted.

A mounting, positive consumer sentiment about the health benefits of cannabinoids is broadly underscored by the work of developers such as GW Pharmaceuticals, whose CBD-based Epidiolex is already FDA-approved to treat two types of severe childhood epilepsy. CBD is going mainstream, with high-profile celebrities such as iconic homemaker Martha Stewart publicly coming out in support of the numerous health benefits that CBD is said to have, like lowering stress and anxiety or battling inflammation and pain. It is little wonder that consumers are seeing CBD used as a nutraceutical additive in everything from over-the-counter cosmetics and pet health products, to wildly popular edibles infused with CBD oil.

The cannabis edibles segment is also interesting to many analysts, and recent forecasts such as the Arcview Group’s $4.1 billion by 2022 figure brings into stark relief the immense potential of a market that already ballooned to more than $1 billion last year. BDS Analytics predicts that the same rapid CBD product sales growth seen at dispensaries will continue to occur as the majority of sales shift to general retail stores. An increasingly receptive consumer base is seen driving this trend, as roughly 66% of hemp-derived CBD consumers in the United States now believe in full federal legalization of cannabis in general.

The demand for CBD products now appears to be nothing short of historic, with CPG (consumer packaged goods) companies having never witnessed such an insatiable appetite for a new product type before. CBD, THC and others of the 100 or more cannabinoids found in cannabis appear to show strong potential for gobbling up market share across massive, vulnerable consumables industries, ranging from soft drinks and snack foods to alcoholic beverages and pet aides.

Revolutionary Delivery Technology Could Supercharge Edibles Industry

Unfortunately, the vast majority of edible CBD is being delivered to the human body in an inefficient manner, with most of the CBD simply ending up in the toilet. Typical CBD-infused products utilize industry-standard delivery methods such as MCTs (medium-chain triglyceride) like coconut oil. Such MCTs are a somewhat crude but straightforward approach, offering a rich texture and “mouth feel” but promising only limited delivery of CBD. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) patented formulations have considerable disruptive potential amid the ongoing CBD boom, with recent multi-objective animal studies showing a clear advantage over industry standards, in terms of how efficiently edible forms of cannabinoids enter the bloodstream.

The company’s standard DehydraTECH formulation using LCFAs (long-chain fatty acids) went head-to-head with a concentration-matched MCT formulation in the recently announced animal studies, yielding a whopping 475% higher CBD blood concentration level — and at four times the speed (15 minutes). These days, it is not uncommon to see people throwing around terms such revolutionary or groundbreaking willy-nilly. So when a technology comes along that truly does represent a fundamental paradigm shift, it can easily get lost in the ceaseless 24-hour news cycle cacophony.

Those words may truly apply here. Lexaria’s patented LCFA formulation has demonstrated a stunning 334% higher average maximum CBD blood concentration level over a 60-minute interval than standard MCT oil formulation, with initial onset (measurable CBD in blood) occurring three times faster (as little as only two minutes), a key factor for edibles.

This animal-study data is compelling and establishes a solid foundation under LXRP’s value proposition to investors. That proposition become even more interesting considering that LXRP is the only company in the United States with such a powerful absorption and delivery technology backed up by proven claims in lab, animal and even human clinical studies. DehydraTECH appears to deliver more CBD, more quickly, than virtually any other brand or technology available in the country.

In a recent human clinical study conducted at a medical research university, DehydraTECH-enabled capsules branded as TurboCBD delivered 317% more CBD into the human bloodstream than did generic CBD lacking this impressive technology. Seemingly, the human testing in addition to animal reinforces the notion that the industry may be witnessing a revolutionary breakthrough.

No Brag, Just Facts

Consider what this technology could mean for the CBD edibles space. At 15 minutes, the DehydraTECH formulation achieved 475% higher concentrations and to levels not seen or achieved by MCT. This puts DehydraTECH on par with inhalation in terms of how fast acting it is, something which has been a brass ring to the edibles industry for many years.

Rapid uptake by the body’s various tissue systems as opposed to valuable raw ingredients being flushed down the toilet because of minimal absorption — that is a huge selling point to consumers. And DehydraTECH technology provides the additional benefit of enabling lower drug-dosage quantities, an important point to consider given that “Lexaria has every reason to believe that virtually identical results would have been achieved if THC was instead the cannabinoid under examination [in the aforementioned animal studies], consistent with subjective human clinical studies Lexaria’s partners have conducted with edible THC products.”

Another great feature of LXRP’s proprietary technology is that it eliminates bad tastes typically found in CBD oils, thus eliminating the need for large quantities of sugar or artificial sweeteners to mask the taste, making the ingredient even more attractive to health-conscious consumers.

CBD Companies Leading the Charge

Cannabis is going mainstream, with CBD appearing to lead the way.

GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF) has the enviable distinction of developing Epidiolex, one of the most widely known CBD indications ever devised. Made world famous by coverage of the drug’s use in combatting severe childhood epilepsy, the drug is the first prescription, FDA-approved, plant-derived cannabinoid medicine in the United States and has acted as a kind brand ambassador for CBD in general.

Tilray Inc. (NASDAQ: TLRY) has grown into quite an operation, with a presence in eight countries across four continents, and worldwide production capacity that is on track to hit 1.3 million square feet this year. A strategic partnership with Authentic Brands Group is expected to have co-branded CBD products hitting consumers throughout ABG’s vast North American distribution network in the second half of this year. And Tilray even managed to beat first-quarter sales expectations, having posted a 195% jump in year-over-year revenues to $23 million, on the strength of factors such as solid hemp-food sales growth from the recently acquired Manitoba Harvest.

MariMed Inc. (OTCQB: MRMD) recently announced the formation of a wholly owned subsidiary to be entirely focused on hemp-derived CBD products. MariMed Hemp Inc. will have its own dedicated executive team, proprietary brand and product lines, as well as distribution and marketing relationships. A bold move for this multistate operator of licensed cannabis facilities, which has an increasingly strong presence in branded cannabis and hemp product lines, as well as a retained initial core business providing advisory services.

Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB) recently made a huge announcement with entry into a multiyear, multimillion-dollar agreement with mixed martial arts organization UFC to conduct hemp-derived CBD research on athlete recovery and wellness at UFC’s substantial Las Vegas institute site. This high-profile and well-capitalized initiative could pave the way for sweeping clinical studies to more thoroughly evaluate CBD across the gamut of current major target indications such as pain management, inflammation, injury/exercise recovery and mental well-being.

Lexaria’s DehydraTECH continues to offer hardline absorption data that makes it one of the most exciting names in CBD delivery technology today. As the CBD industry continues to build momentum approaching widespread, mainstream acceptance and inevitable incorporation into a multiplicity of everyday consumers products and foods, LXRP stands poised to profit mightily.

For more information on Lexaria Bioscience Corp., visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Benzinga Cannabis Capital Conference Will Bring Cannabis Visionaries and Investors Together

  • Presented by Benzinga, the upcoming cannabis conference will be held at the Eden Roc in Miami Beach, Florida; it is the go-to source event for investors who want the latest news and opportunities from the burgeoning sector
  • The conference will kick off on January 15 with an invite-only C-Suite retreat for cannabis operators; the audience will be just 100 C-Suite executives; a pre-retreat reception will be held the night prior
  • The conference will feature company presentations, networking receptions and an all-star lineup of knowledgeable keynote speakers talking about the global opportunities for cannabis

Benzinga Cannabis Capital Conference (CCC) will offer attendees a fast-paced comprehensive lineup of speed networking, a specially selected lineup of keynoters, corporate presentations for investors and a look at the future of cannabis internationally. It will be held January 15-16 at the Eden Roc in Miami Beach (www.BenzingaCannabisConference.com).

The attendee mix is expected to consist of 25 percent institutional investors, 20 percent retail investors, 40 percent public cannabis companies, 10 percent private cannabis companies and five percent media.

Reserve your place and book hotel rooms for CCC now at http://cnw.fm/42sPg. Be sure to learn more about how you can qualify for special discounted tickets and hotel rooms.

“Benzinga’s Cannabis Capital Conference brings together the crème de la crème of the cannabis world,” Neal Hamilton, vice president of marketing for Benzinga, stated in a recent press release. “Benzinga has long presided as a financial media leader, offering broad coverage relative to the cannabis space. We now bring that standout expertise to a live setting where entrepreneurs and investors can network, forge deals and learn from today’s top cannabis influencers, policymakers and innovators.”

CCC will showcase the following public and private companies:

  • AmeriCann Inc. (OTCQB: ACAN)
  • Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB)
  • Cannex Capital Holdings Inc. (CSE: CNNX) (OTCQX: CNXXF)
  • Harvest Health & Recreation Inc. (CSE: HARV)
  • CEDR HR Solutions
  • CuraLeaf Holdings Inc. (CSE: CURA)
  • DionyMed Brands Inc. (OTC: HMDEF)
  • Growcentia
  • iAnthus Capital Holdings Inc. (CSE: IAN) (OTCQX: ITHUF)
  • InMed Pharmaceuticals Inc. (OTCQX: IMLFF) (TSX: IN)
  • KushCo Holdings Inc. (OTCQB: KSHB)
  • LGC Capital Ltd. (TSX.V: LG)
  • Liberty Health Sciences Inc. (OTCQX: LHSIF)
  • MariMed Inc. (OTCQB: MRMD)
  • Medicine Man Technologies Inc. (OTCQX: MDCL)
  • Medipharm Labs Corp. (TSX.V: LABS)
  • MJ Freeway
  • New Frontier Data
  • Newstrike Brands Ltd. (TSX.V: HIP)
  • Plus Products Inc. (CSE: PLUS)
  • Pure Global Cannabis Inc. (OTC: PRCNF) (TSX.V: PURE)
  • Radicle Inc./Gage Cannabis
  • Starbuds/Compass Cannabis
  • Trulieve Cannabis Corp. (CSE: TRUL) (OTC: TCNNF)
  • Valens GroWorks Corp. (OTCQB: MYMSF)
  • Wayland Group Corp. (OTCQB: MRRCF) (CSE: WAYL)
  • High Tide Inc. (CSE: HITI)

For more information, visit the event’s website at www.BenzingaCannabisConference.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

CannabisNewsWire is at the epicenter of the Cannabis Revolution.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Flow of Finance Funds Acquisitions and Investment Across the Cannabis Sector

CannabisNewsWire Editorial Coverage: A growing market is supporting a wave of acquisitions and cross-company investments in the cannabis industry.

  • Significant growth in the cannabis industry is supporting a range of multimillion-dollar investments.
  • Some of these have taken the form of acquisitions, as innovators evolve into established companies.
  • Others are cross-company investments, some within the sector and some from outside.
  • Profits are coming not just from cannabis itself but from support services, with companies profiting from pick-and-shovel plays.

One of the companies making a pick-and-shovel play is Sugarmade, Inc. (OTCQB: SGMD) (SGMD Profile), which is expanding its position in cultivation supplies through acquisitions and marketing agreements. GW Pharmaceuticals Plc (NASDAQ: GWPH) recently carried out a public offering to fund further growth, raising $345 million to expand its cannabis-oriented pharmaceuticals work. AbbVie, Inc. (NYSE: ABBV), on the other hand, has retained only a limited connection to cannabis, moving instead into other treatments. Specialist consulting company MariMed, Inc. (OTCQB: MRMD) provides advice for those looking to expand in the sector, covering the development and management of cultivation facilities, and recently investing in a related software company. For Medmen Enterprises, Inc. (OTCQX: MMNFF) (CSE: MMEN), expansion means a vertically integrated supply chain across four US states as it expands a carefully developed brand.

Cannabis Acquisitions Continue as Companies Seek Liquidity

With the completion of cannabis legalization in Canada, investors are watching closely to see what effect this will have on the market. Over less than 20 years, cannabis has evolved from nothing into a multimillion-dollar industry, with companies ranging from cultivators and retailers to payment specialists and equipment suppliers. As it continues to expand at a rapid rate in both Canada and the US, the market is seeing growth for players both big and small.

To fuel this development, many companies are looking for fresh finance. Liquidity is needed to fund research, development, and expansion, from building larger cultivation facilities to setting up new retail outlets. This is both driven by and driving a wave of new finance deals and acquisitions, as the sector matures and consolidates its resources.

Acquiring the Fundamentals

The appeal of acquisitions is driving the strategy of companies such as hydroponics supplier Sugarmade, Inc. (OTCQB: SGMD). Hydroponic equipment is essential to the indoor cultivation of cannabis, so the growth of the sector promises a boom in demand for hydroponics. Sugarmade is using this boom to attract additional finance and undertake a raft of acquisitions, with an end goal of becoming a major player not just in hydroponics but in the cannabis space itself.

Such acquisitions have taken off in a big way over the past year. The first half of 2018 saw 145 mergers and acquisitions in the cannabis sector, nearly double the number for the same period in 2017. Some of these represent consolidation by existing cannabis players, as they mature from innovative startups into established businesses in a widely accepted field. But money is also coming in from the outside, for example through Constellation Brands’ acquisition of a large portion of Canopy Growth.

A pattern is emerging of cannabis-adjacent companies moving directly into the sector. For a company such as Constellation, the move is a sideways one from investment in alcohol to one in cannabis, protecting its place in the recreational consumables market. It’s the same play that other alcohol and tobacco companies are eyeing. For Sugarmade, acquisitions represent expansion within its existing business, ensuring a firm hold on hydroponics, as well as a move up and down the supply chain to better profit from the businesses it is already tied to.

A Pick-and-Shovel Strategy

Earlier this year, Sugarmade announced that it was moving to acquire two other suppliers of cultivation equipment. Now details of those deals are emerging, with the signing of a binding Letter of Intent (“LOI”) to acquire Sky Unlimited, LLC. This could allow Sugarmade to expand its distribution channels, thanks to the different models followed by the two companies. While Sugarmade’s sales to the cannabis sector primarily come through online buyers, Sky Unlimited specializes in selling to wholesalers and large commercial cultivators. Combining the two may create manufacturing, logistical, and marketing efficiencies across an expanded customer base.

“The trend in cannabis cultivation is toward the larger commercial cultivation operations, and Sky Unlimited is in the thick of that dynamic marketplace,” said Jimmy Chan, CEO of Sugarmade. “This year, Sky Unlimited and its associated operations are expected to produce in excess of $40 million in revenues with profitability and positive cash flow. This new revenue stream combined with our recently upwardly guided revenue forecast of $30 million for next year will make Sugarmade one of the largest publicly traded suppliers to the booming cannabis cultivation marketplace, with a combined revenue forecast for next year in excess of $70 million.”

The types of company being targeted by Sugarmade reveal a pick-and-shovel strategy. Rather than making a direct jump into cannabis, the company is investing in the underlying products and services cannabis suppliers need. It’s a more conservative move than investing directly in cannabis, one that will buffer Sugarmade against the immediate effects of a fast-changing and still controversial sector, while letting it profit from the sector’s growth.

Following a previous Master Marketing Agreement with BizRight, this latest move makes Sugarmade one of the largest publicly traded cannabis supply companies. The company shows no sign of stopping there, having announced its intention to continue with an expansion strategy. The next likely move may well be brand acquisition, providing a higher price-to-earnings ratio for investors. Having already made an acquisition proposal for a Washington state retailer with $5 million in annual revenues, Sugarmade is on its way to becoming a more public fixture in the cannabis market.

Financing Growth in Cannabis

As in any sector, the success of expansion strategies will depend upon their liquidity. Fortunately, the state of the cannabis market appears to currently ensure a steady stream of finance. The US cannabis market alone is expected to be worth $10 billion in 2018, 50 percent more than it was only two years ago. Canada’s market is also expected to be worth billions, as legalization transfers the recreational consumer base from illegal dealers to legitimate businesses.

Cannabis companies are using this opportunity to channel finance into growth. Some are striking deals for bank loans in newly legalized regions, while others are using public offerings to raise fresh finance through sales of shares.

Sugarmade is taking a different approach, using expansion to fund further expansion. Following the BizRight and Sky Unlimited deals, the company has upgraded its projections for revenue in 2019 from $6 million to $70 million. Its previous deals will now provide the liquidity for future acquisitions, allowing a rolling strategy of expansion across the sector.

The pick-and-shovel plays look to pay off.

Cannabis Companies Making Big Moves

As the market keeps growing, so do many of the companies working in cannabis.

GW Pharmaceuticals Plc (NASDAQ: GWPH) is a world leader in the development of cannabis-related medicines, thanks to its strong research program and manufacturing expertise. Already a major player in the sector, the company has recently sought funds for expansion through a public offering. The result was an extra $345 million in funds, reflecting investors’ faith in the cannabis sector and in the future of companies such as GW. These funding will allow the company to keep growing its research and production work, with that research work expanding its portfolio of cannabis-related intellectual property.

While some companies invest more heavily in cannabis, others are diversifying. Pharmaceuticals manufacturer AbbVie, Inc. (NYSE: ABBV) is the company behind Marinol, a drug used to tackle appetite loss due to AIDS and cancer treatments. But while Marinol’s active ingredient is chemically identical to THC, the best-known active ingredient in cannabis, the company has filed only a handful of patents relating to cannabis and shows no sign of expansion into the sector. It’s a move that may help AbbVie in marketing to cannabis’s opponents, but one that leaves the space open for competitors.

The expansion of cannabis companies has supported the emergence of specialist support services, such as those provided by MariMed, Inc. (OTCQB: MRMD). A cannabis consulting firm, MariMed provides professional guidance on the development, funding, and operation of cultivation facilities. This can help other firms navigate the complicated issues surrounding the industry, covering everything from real estate to regulatory compliance. The company recently invested in Sprout, a software company supporting cannabis brands and dispensaries, allowing it to bundle software with its other business solutions.

Medmen Enterprises, Inc. (OTCQX: MMNFF) (CSE: MMEN),  has used expansion to develop a vertically integrated supply chain. The company works in both cultivation and retail, meaning that it handles the product all the way from planting first seedlings to placing packaged cannabis into customers’ hands. Its recent acquisition of dispensary and cultivation facilities from Treadwell Simpson Partnership means that it is spreading its carefully managed brand from existing bases in California, Nevada, and New York into Florida.

The growth of the cannabis market is providing a flow of finance, leading to acquisitions and cross-company investments across the sector.

For more information on Sugarmade, visit Sugarmade, Inc. (OTCQB: SGMD)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.